Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients

World Journal of Gastroenterology

Volumn 16, Issue 48, 2010, Pages 6155-6162

  Jiang, Jing Ting ^a,b   Shen, Yue Ping ^b   Wu, Chang Ping ^a   Zhu, Yi Bei ^a,b   Wei, Wen Xiang ^b   Chen, Lu Jun ^a   Zheng, Xiao ^a   Sun, Jing ^b   Lu, Bin Feng ^c   Zhang, Xue Guang ^b  

^a THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cytokine induced killer cells; Gastric cancer; Immunotherapy; Probability; Survival analysis

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; DEMOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OPERATION DURATION; QUESTIONNAIRE; RISK FACTOR; STOMACH CANCER; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

EID: 78650799848     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i48.6155     Document Type: Article

References (52)

1. Shang J, Pena AS. Multidisciplinary approach to understand the pathogenesis of gastric cancer. World J Gastroenterol 2005; 11: 4131-4139
2. Shen X, Zhang J, Yan Y, Yang Y, Fu G, Pu Y. Analysis and estimates of the attributable risk for environmental and genetic risk factors in gastric cancer in a Chinese population. J Toxicol Environ Health A 2009; 72: 759-766
3. Varadhachary G, Ajani JA. Gastric cancer. Clin Adv Hematol Oncol 2005; 3: 118-124
4. Valentini V, Cellini F, Minsky BD, Mattiucci GC, Balducci M, D'Agostino G, D'Angelo E, Dinapoli N, Nicolotti N, Valentini C, La Torre G. Survival after radiotherapy in gastric cancer: systematic review and meta-analysis. Radiother Oncol 2009; 92: 176-183
5. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999; 83: 18-29
6. Ajani JA. Evolving chemotherapy for advanced gastric cancer. Oncologist 2005; 10 Suppl 3: 49-58
7. Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E. Gastric cancer. Crit Rev Oncol Hematol 2005; 54: 209-241
8. Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol 2009; 27: 83-117
9. Stroncek D, Berlyne D, Fox B, Gee A, Heimfeld S, Lindblad R, Loper K, McKenna D Jr, Rooney C, Sabatino M, Wagner E, Whiteside T, Wood D, Heath-Mondoro T. Developments in clinical cell therapy. Cytotherapy 2010; 12: 425-428
10. Hontscha C, Borck Y, Zhou H, Messmer D, Schmidt-Wolf IG. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 2010; Epub ahead of print
11. Rosenberg S. Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. J Natl Cancer Inst 1985; 75: 595-603
12. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 233: 1318-1321
13. Yun YS, Hargrove ME, Ting CC. In vivo antitumor activity of anti-CD3-induced activated killer cells. Cancer Res 1989; 49: 4770-4774
14. Takahashi H, Nakada T, Puisieux I. Inhibition of human colon cancer growth by antibody-directed human LAK cells in SCID mice. Science 1993; 259: 1460-1463
15. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 1991; 174: 139-149
16. Schmidt-Wolf IG, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, Weissman IL, Negrin RS. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 1993; 21: 1673-1679
17. Jiang J, Xu N, Wu C, Deng H, Lu M, Li M, Xu B, Wu J, Wang R, Xu J, Nilsson-Ehle P. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokineinduced killer cells. Anticancer Res 2006; 26: 2237-2242
18. Jiang JT, Wu CP, Shi LR, Xu N, Deng HF, Lu MY, Ji M, Zhu YB, Zhang XG. Side effects during treatment of advanced gastric carcinoma by chemotherapy combined with CIK-cell transfusion in elderly people. Chin J Clin Oncol 2008; 5: 79-82
19. Jiang J, Zhu Y, Wu C, Shen Y, Wei W, Chen L, Zheng X, Sun J, Lu B, Zhang X. Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer. Cancer Immunol Immunother 2010; 59: 1707-1714
20. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000; 87: 236-242
21. Jiang JT, Wu CP, Deng HF, Lu MY, Li M, Wang H, Wu J. Compare cytotoxicity of cytokine-induced killer cells with tumor infiltrating lymphocytes in vitro. Jianyan Yixue 2005; 20: 322-324
22. De Vita F, Orditura M, Matano E, Bianco R, Carlomagno C, Infusino S, Damiano V, Simeone E, Diadema MR, Lieto E, Castellano P, Pepe S, De Placido S, Galizia G, Di Martino N, Ciardiello F, Catalano G, Bianco AR. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer 2005; 92: 1644-1649
23. Schoenfeld DA, Richter JR. Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics 1982; 38: 163-170
24. Chen L, Tian H, Chen J, He ZG, Tao SF, Lokesh G, Peng SY. Surgical management of gastric stump cancer: a report of 37 cases. J Zhejiang Univ Sci B 2005; 6: 38-42
25. Kollmannsberger C, Budach W, Stahl M, Schleucher N, Hehr T, Wilke H, Schleicher J, Vanhoefer U, Jehle EC, Oechsle K, Trarbach T, Boehlke I, Kanz L, Hartmann JT, Bokemeyer C. Adjuvant chemoradiation using 5-fluorouracil/ folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ ACO. Ann Oncol 2005; 16: 1326-1333
26. Lin WL, Li DG, Chen Q, Lu HM. Clinical and experimental study of oxaliplatin in treating human gastric carcinoma. World J Gastroenterol 2004; 10: 2911-2915
27. Abe M, Nishimura Y, Shibamoto Y. Intraoperative radiation therapy for gastric cancer. World J Surg 1995; 19: 544-547
28. Klautke G, Foitzik T, Ludwig K, Ketterer P, Klar E, Fietkau R. Neoadjuvant radiochemotherapy in locally advanced gastric carcinoma. Strahlenther Onkol 2004; 180: 695-700
29. Zuo Y, Xu M, Shen D, Lu WD, Lu JF. [Postoperative intraperitioneal hyperthermic chemoperfusion combined with intravenous chemotherapy for 82 advanced gastric cancer patients] Zhonghua Zhongliu Zazhi 2004; 26: 247-249
30. Bozzetti F, Vaglini M, Deraco M. Intraperitoneal hyperthermic chemotherapy in gastric cancer: rationale for a new approach. Tumori 1998; 84: 483-488
31. Yu QS, Zhang FZ, Tang XR. [Clinical study on early use of Chinese medicinal herbs and chemotherapy after operation of gastric cancer] Zhongguo Zhongxiyi Jiehe Zazhi 1995; 15: 459-461
32. Wang GT. [Treatment of operated late gastric carcinoma with prescription of strengthening the patient's resistance and dispelling the invading evil in combination with chemotherapy: follow-up study of 158 patients and experimental study in animals] Zhongxiyi Jiehe Zazhi 1990; 10: 712-716, 707
33. Yamaguchi K, Shimamura T, Hyodo I, Koizumi W, Doi T, Narahara H, Komatsu Y, Kato T, Saitoh S, Akiya T, Munakata M, Miyata Y, Maeda Y, Takiuchi H, Nakano S, Esaki T, Kinjo F, Sakata Y. Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. Br J Cancer 2006; 94: 1803-1808
34. Herberman RB. Cancer therapy by biological response modifiers. Clin Physiol Biochem 1987; 5: 238-248
35. Margolin KA, Negrin RS, Wong KK, Chatterjee S, Wright C, Forman SJ. Cellular immunotherapy and autologous transplantation for hematologic malignancy. Immunol Rev 1997; 157: 231-240
36. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730
37. Haynes NM, van der Most RG, Lake RA, Smyth MJ. Immunogenic anti-cancer chemotherapy as an emerging concept. Curr Opin Immunol 2008; 20: 545-557
38. Wu K, Nie Y, Guo C, Chen Y, Ding J, Fan D. Molecular basis of therapeutic approaches to gastric cancer. J Gastroenterol Hepatol 2009; 24: 37-41
39. Larmonier N, Fraszczak J, Lakomy D, Bonnotte B, Katsanis E. Killer dendritic cells and their potential for cancer immunotherapy. Cancer Immunol Immunother 2010; 59: 1-11
40. Hoffman DM, Gitlitz BJ, Belldegrun A, Figlin RA. Adoptive cellular therapy. Semin Oncol 2000; 27: 221-233
41. Lu PH, Negrin RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994; 153: 1687-1696
42. Gritzapis AD, Dimitroulopoulos D, Paraskevas E, Baxevanis CN, Papamichail M. Large-scale expansion of CD3(+)CD56(+) lymphocytes capable of lysing autologous tumor cells with cytokine-rich supernatants. Cancer Immunol Immunother 2002; 51: 440-448
43. Johnson BE, Bridges JD, Sobczeck M, Gray J, Linnoila RI, Gazdar AF, Hankins L, Steinberg SM, Edison M, Frame JN, Pass H, Nesbitt J, Holden D, Mulshine JL, Glatstein E, Ihde DC. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/ cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. J Clin Oncol 1996; 14: 806-813
44. Scheffold C, Brandt K, Johnston V, Lefterova P, Degen B, Schöntube M, Huhn D, Neubauer A, Schmidt-Wolf IG. Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia. Bone Marrow Transplant 1995; 15: 33-39
45. Schmidt-Wolf IG, Lefterova P, Johnston V, Scheffold C, Csipai M, Mehta BA, Tsuruo T, Huhn D, Negrin RS. Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells. Cell Immunol 1996; 169: 85-90
46. Verneris MR, Kornacker M, Mailänder V, Negrin RS. Resistance of ex vivo expanded CD3+CD56+ T cells to Fas-mediated apoptosis. Cancer Immunol Immunother 2000; 49: 335-345
47. Chen FX, Liu JQ, Zhang NZ, Gong XJ, Zhang GL, Xu YM, Zhou ZH, Wang T, Huang J. [Clinical observation on adoptive immunotherapy with autologous cytokine-induced killer cells for advanced malignant tumor] Ai Zheng 2002; 21: 797-801
48. Wu C, Jiang J, Shi L, Xu N. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res 2008; 28: 3997-4002
49. Olioso P, Giancola R, Di Riti M, Contento A, Accorsi P, Iacone A. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol 2009; 27: 130-139
50. Kim HM, Lim J, Yoon YD, Ahn JM, Kang JS, Lee K, Park SK, Jeong YJ, Kim JM, Han G, Yang KH, Kim YJ, Kim Y, Han SB. Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma. Int Immunopharmacol 2007; 7: 1793-1801
51. Cho MY, Joh YG, Kim NR, Jung SI, Bae JW, Kim YC, Koo BH, Whang CW, Suh SO. T-lymphocyte subsets in patients with AJCC stage III gastric cancer during postoperative adjuvant chemotherapy. American Joint Committee on Cancer. Scand J Surg 2002; 91: 172-177
52. Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E. Gastric cancer. Crit Rev Oncol Hematol 2009; 71: 127-164